Needham Maintains Buy on ShockWave Medical, Raises Price Target to $286
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on ShockWave Medical (NASDAQ:SWAV) and raises the price target from $260 to $286.
February 16, 2024 | 10:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson maintains a Buy rating on ShockWave Medical and raises the price target from $260 to $286.
The increase in price target by a reputable analyst suggests a positive outlook on ShockWave Medical's future performance. This typically leads to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100